comparemela.com
Home
Live Updates
Nephrology Collaborative Group - Breaking News
Pages:
2
3
4
5
6
7
8
Latest Breaking News On - Nephrology collaborative group - Page 1 : comparemela.com
ABIM Announces New Specialty Board Members
The American Board of Internal Medicine (ABIM) announced new appointments to its Specialty Boards and Approval Committees today.
United states
New orleans
Dana farber cancer institute
Fox chase
Providence alaska medical center
New york
Stanford university
Thomas jefferson university
University of washington
University of rochester
Puget sound
Los angeles
West jefferson medical center
University of southern california
West reading
Drexel university
ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
Key Highlights: Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 in patients with. | May 12, 2023
Fernandoc fervenza
Douglas golenbock
Margery blacklow
Danielc cattran
Stephenc glover
Casey mcdonald
Richardj glassock
Dave schemelia
Umass chan medical school
Division of infectious diseases
Zyversa therapeutics inc
Securities exchange
Nephrology collaborative group
Mayo graduate school of medicine
David geffen school of medicine
University of toronto
ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200
/PRNewswire/ ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for.
United states
Alessia fornoni
Danielc cattran
Sharong adler
Fernandoc fervenza
Debbies gipson
Stephenc glover
Pabloa guzman
Pablo guzman
Marlene haffner
Division of nephrology
University of toronto
Founder of orphan solutions
Products development
Department of pediatrics at university michigan
Katz family division of nephrology
ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200
/PRNewswire/ ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for.
United states
Alessia fornoni
Danielc cattran
Sharong adler
Fernandoc fervenza
Debbies gipson
Stephenc glover
Pabloa guzman
Pablo guzman
Marlene haffner
Division of nephrology
University of toronto
Founder of orphan solutions
Products development
Department of pediatrics at university michigan
Katz family division of nephrology
ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200
Drs. Daniel C. Cattran and Fernando C. Fervenza join ZyVersa s distinguished group of Scientific AdvisorsVAR 200 is a phase 2a-ready cholesterol e.
United states
Alessia fornoni
Danielc cattran
Sharong adler
Fernandoc fervenza
Debbies gipson
Stephenc glover
Pabloa guzman
Pablo guzman
Marlene haffner
Division of nephrology
University of toronto
Founder of orphan solutions
Products development
Department of pediatrics at university michigan
Katz family division of nephrology
vimarsana © 2020. All Rights Reserved.